Filed Pursuant to Rule 424(b)(3)
File No. 333-136277
Prospectus
supplement no. 46
to prospectus dated november 6, 2019
ZIM
CORPORATION
This Prospectus Supplement No. 46 supplements
and amends our Prospectus dated July 11, 2008, as amended and supplemented. This Prospectus Supplement No. 46 includes our attached
Form 6-K for the month of November, 2019 as filed with the Securities and Exchange Commission on November 6, 2019.
Any statement contained in the Prospectus
and any prospectus supplements filed prior to the date hereof shall be deemed to be modified or superseded to the extent that information
in this Prospectus Supplement No. 46 modifies or supersedes such statement. Any statement that is modified or superseded shall
not be deemed to constitute a part of the Prospectus except as modified or superseded by this Prospectus Supplement No. 46.
This Prospectus Supplement No. 46 should
be read in conjunction with the Prospectus, and any prospectus supplements filed prior to the date hereof.
The date of this Prospectus Supplement
No. 46 is November 6, 2019.
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
6 – K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For
the month of November, 2019
Commission
File Number 0-31691
ZIM
CORPORATION
150
Isabella Street, Suite 150
Ottawa,
Ontario
Canada
K1S 1V7
(Address
of Principal Executive Office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F [X] Form 40-F [ ]
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T
Rule 101(b)(1): [ ]____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T
Rule 101(b)(7): ____
Quarterly
Business Review by Management for the
Quarter
Ended September 30, 2019
TABLE
OF CONTENTS
Item
1.
|
|
Selected Financial Data
|
3
|
|
|
|
|
Item 2.
|
|
Quarterly Business Review
|
8
|
|
|
|
|
Item 3.
|
|
Quantitative and Qualitative Disclosures
About Market Risks
|
14
|
|
|
|
|
Item 4.
|
|
2018 Annual General Meeting
|
16
|
|
|
|
|
Signatures
|
|
|
17
|
ITEM
1 – SELECTED FINANCIAL DATA
ZIM Corporation
|
|
|
|
|
Condensed Consolidated
Balance Sheets
|
|
|
|
|
(Expressed in US dollars,
except for share data)
|
|
|
|
|
|
|
|
|
|
|
|
September
30,
|
|
|
|
|
2019
|
|
March
31,
|
|
|
(Unaudited)
|
|
2019
|
ASSETS
|
|
$
|
|
$
|
Current
assets
|
|
|
|
|
|
|
|
|
Cash
and cash equivalents
|
|
|
429,202
|
|
|
|
506,524
|
|
Accounts
receivable, net
|
|
|
281,402
|
|
|
|
59,631
|
|
Investment
tax credits receivable
Other
tax credits
|
|
|
44,185
34,345
|
|
|
|
171,204
35,351
|
|
Prepaid
expenses
|
|
|
13,779
|
|
|
|
27,911
|
|
|
|
|
802,913
|
|
|
|
800,621
|
|
Investment
|
|
|
715,472
|
|
|
|
709,047
|
|
Right
of uses assets
|
|
|
8,440
|
|
|
|
—
|
|
Property
and equipment, net
|
|
|
23,402
|
|
|
|
20,799
|
|
|
|
|
1,550,227
|
|
|
|
1,530,467
|
|
LIABILITIES
AND SHAREHOLDERS' EQUITY
|
|
|
|
|
|
|
|
|
Current
liabilities
|
|
|
|
|
|
|
|
|
Accounts
payable
|
|
|
19,962
|
|
|
|
36,802
|
|
Current
lease liabilities
|
|
|
9,104
|
|
|
|
—
|
|
Accrued
liabilities
|
|
|
21,188
|
|
|
|
21,487
|
|
Deferred
revenue
|
|
|
73,339
|
|
|
|
89,844
|
|
Total
liabilities
|
|
|
123,593
|
|
|
|
148,133
|
|
Shareholders'
equity:
|
|
|
|
|
|
|
|
|
Preferred shares,
no par value, non-cumulative
|
|
|
—
|
|
|
|
—
|
|
dividend
at a rate to be determined by the Board of Directors redeemable for CDN $1 per share. Unlimited authorized shares;
issued and outstanding NIL shares at September 30, 2019 and March 31, 2019.
|
|
|
|
|
|
|
|
|
Special shares,
no par value, non-voting,
|
|
|
|
|
|
|
|
|
Unlimited
authorized shares; issued and outstanding NIL shares at September 30, 2019 and March 31, 2019.
|
|
|
—
|
|
|
|
—
|
|
Common shares, no
par value, voting,
|
|
|
|
|
|
|
|
|
Unlimited authorized
shares; 8,136,348 shares issued and outstanding as at September 30, 2019 and 8,136,348 as at March 31, 2019.
|
|
|
19,491,842
|
|
|
|
19,491,842
|
|
Additional
paid-in capital
|
|
|
2,963,912
|
|
|
|
2,963,912
|
|
Accumulated
deficit
|
|
|
(20,564,789
|
)
|
|
|
(20,622,106
|
)
|
Accumulated
other comprehensive income
|
|
|
(464,331
|
)
|
|
|
(451,314
|
)
|
|
|
|
1,426,331
|
|
|
|
1,382,334
|
|
|
|
|
1,550,227
|
|
|
|
1,530,467
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ZIM
Corporation
Condensed
Consolidated Statements of Operations
|
|
|
|
|
|
|
|
|
(Expressed in US dollars)
|
|
|
|
|
|
|
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three
months
ended September
30, 2019
|
|
Three
months
ended September
30, 2018
|
|
Six
months
ended September
30, 2019
|
|
Six
months
ended September
30, 2018
|
|
|
$
|
|
$
|
|
$
|
|
$
|
Revenues
|
|
|
|
|
|
|
|
|
Mobile
|
|
|
12,227
|
|
|
|
27,127
|
|
|
|
37,104
|
|
|
|
51,376
|
|
Software
|
|
|
17,536
|
|
|
|
1,828
|
|
|
|
20,723
|
|
|
|
98,963
|
|
Software
maintenance and consulting
|
|
|
77,917
|
|
|
|
78,700
|
|
|
|
138,667
|
|
|
|
166,825
|
|
Total
revenues
|
|
|
107,680
|
|
|
|
107,655
|
|
|
|
196,494
|
|
|
|
317,164
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenues
|
|
|
5,867
|
|
|
|
4,789
|
|
|
|
10,679
|
|
|
|
8,139
|
|
Selling,
general and administrative
|
|
|
137,661
|
|
|
|
176,458
|
|
|
|
296,765
|
|
|
|
295,996
|
|
Research
and development
|
|
|
47,323
|
|
|
|
67,063
|
|
|
|
99,742
|
|
|
|
119,525
|
|
Total
operating expenses
|
|
|
190,851
|
|
|
|
248,310
|
|
|
|
407,186
|
|
|
|
423,660
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss
from operations
|
|
|
(83,171
|
)
|
|
|
(140,655
|
)
|
|
|
(210,692
|
)
|
|
|
(106,496
|
)
|
Other
income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized
gain on equity investments
|
|
|
-
|
|
|
|
10,302
|
|
|
|
-
|
|
|
|
608,343
|
|
Gain on sale of investments
|
|
|
216,901
|
|
|
|
-
|
|
|
|
216,901
|
|
|
|
-
|
|
Other
income (loss)
|
|
|
(162
|
)
|
|
|
6,987
|
|
|
|
(162
|
)
|
|
|
6,987
|
|
Interest
income, net
|
|
|
3,094
|
|
|
|
2,536
|
|
|
|
6,852
|
|
|
|
5,881
|
|
Total
other income
|
|
|
219,833
|
|
|
|
19,825
|
|
|
|
223,591
|
|
|
|
621,211
|
|
Net
income (loss) before income taxes
|
|
|
136,662
|
|
|
|
(120,830
|
)
|
|
|
12,899
|
|
|
|
514,715
|
|
Income
tax benefit
|
|
|
25,603
|
|
|
|
12,878
|
|
|
|
44,418
|
|
|
|
31,863
|
|
Net
income (loss)
|
|
|
162,265
|
|
|
|
(107,952
|
)
|
|
|
57,317
|
|
|
|
546,578
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
and fully diluted income (loss) per share
|
|
|
0.020
|
|
|
|
(0.013
|
)
|
|
|
0.007
|
|
|
|
0.067
|
|
Weighted
average number of shares outstanding
|
|
|
8,136,348
|
|
|
|
8,136,348
|
|
|
|
8,136,348
|
|
|
|
8,136,348
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ZIM
Corporation
Condensed
Consolidated Statements of Cash Flows
|
|
|
|
|
(Expressed in US dollars)
|
|
|
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
Six months ended
September 30, 2019
|
|
Six months ended
September
30, 2018
|
|
|
$
|
|
$
|
OPERATING
ACTIVITIES
|
|
|
|
|
|
|
|
|
Net
income
|
|
|
57,317
|
|
|
|
546,578
|
|
Items
not involving cash:
|
|
|
|
|
|
|
|
|
Depreciation
of property and equipment
|
|
|
7,821
|
|
|
|
4,401
|
|
Unrealized
gain in equity securities
|
|
|
—
|
|
|
|
—
|
|
Stock-based
compensation
|
|
|
806
|
|
|
|
843
|
|
Changes
in operating working capital
|
|
|
|
|
|
|
|
|
Increase
in accounts receivable
|
|
|
(221,771
|
)
|
|
|
(8,630
|
)
|
Decrease
in investment tax credits receivable
|
|
|
128,025
|
|
|
|
126,079
|
|
Decrease
in prepaid expenses
|
|
|
14,132
|
|
|
|
17,405
|
|
Decrease
in right of use assets
|
|
|
8,440
|
|
|
|
-
|
|
Decrease
in lease liabilities
|
|
|
(9,104
|
)
|
|
|
-
|
|
Increase
in accounts payable
|
|
|
(16,840
|
)
|
|
|
17,751
|
|
Increase
(decrease) in accrued liabilities
|
|
|
(299
|
)
|
|
|
1,264
|
|
Decrease
in deferred revenues
|
|
|
(16,505
|
)
|
|
|
20,480
|
|
Cash
flows provided by operating activities
|
|
|
(47,978
|
)
|
|
|
117,950
|
|
|
|
|
|
|
|
|
|
|
INVESTING
ACTIVITIES
|
|
|
|
|
|
|
|
|
Purchase
of property and equipment
|
|
|
(6,576
|
)
|
|
|
(6,054
|
)
|
Cash
flows used in investing activities
|
|
|
(6,576
|
)
|
|
|
(6,054
|
)
|
|
|
|
|
|
|
|
|
|
FINANCING
ACTIVITIES
|
|
|
—
|
|
|
|
—
|
|
Cash
flows provided by financing activities
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
Effect
of changes in exchange rates on cash
|
|
|
(22,768
|
)
|
|
|
(62,863
|
)
|
|
|
|
|
|
|
|
|
|
Increase
in cash
|
|
|
(77,322
|
)
|
|
|
49,033
|
|
Cash,
beginning of period
|
|
|
506,524
|
|
|
|
418,507
|
|
Cash,
end of period
|
|
|
429,202
|
|
|
|
467,540
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1
- BASIS OF PRESENTATION
The
accompanying unaudited selected financial data of ZIM Corporation (“ZIM” or the “Company”) and its subsidiaries
have been prepared pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”).
Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted
accounting principles in the United States of America (US GAAP) have been condensed or omitted pursuant to such rules and regulations.
The condensed consolidated balance sheet as of September 30, 2019 has been derived from our audited consolidated financial statements
for the year ended March 31, 2019. These selected financial data should be read in conjunction with the financial statements and
notes thereto included in the latest annual report on Form 20-F. These data have been prepared on the same basis as the audited
consolidated financial statements for the year ended March 31, 2019 and, in the opinion of management, include all adjustments
considered necessary for a fair presentation of the financial position, results of operations and cash flows of the Company. Unless
otherwise stated in this Form 6-K the information contained herein has not been audited or reviewed by an independent auditor.
The results of operations for the three month and six month periods ended September 30, 2019 are not necessarily indicative of
the results to be expected for the full year.
2
- GOING CONCERN
These
consolidated financial statements have been prepared on a going concern basis in accordance with accounting principles generally
accepted in the United States ("US GAAP"). The going concern basis of presentation assumes that the Company will
continue in operation for the foreseeable future and be able to realize its assets and discharge its liabilities and commitments
in the normal course of business. To date the Company has incurred an accumulated
loss of $20,564,789 and year to date cash flow used in operations of $47,978. This
raises significant doubt about the ability of the Company to continue as a going concern. The ability of the Company to continue
as a going concern and to realize the carrying value of its assets and discharge
its liabilities and commitments when due is
dependent on the Company generating revenue sufficient to fund its cash flow needs. There is no certainty that this and other
strategies will be sufficient to permit the Company to continue as a going concern.
Management
is currently investigating and evaluating options that may include recapitalization of the Company and pursuing other ventures
of a different nature.
The
consolidated financial statements do not reflect adjustments that would be necessary if
the going concern assumption were not appropriate. If the going concern basis were
not appropriate for these consolidated financial statements, then adjustments would be necessary in
the carrying value of the assets and liabilities, the reported revenue and expenses
and the classifications used in the statement of financial position. Such differences in amounts could be material.
3
– INVESTMENT AND SUBSIDIARIES
Investments
and long term deposits
|
|
Original
Cost
|
|
Carrying
Value – September
30, 2019
|
CP4H
|
|
|
187,367
|
|
|
|
—
|
|
Equispheres
|
|
|
111,990
|
|
|
|
707,166
|
|
HostedBizz
|
|
|
1,005
|
|
|
|
—
|
|
NuvoBio
|
|
|
762
|
|
|
|
755
|
|
Spiderwort
|
|
|
7,725
|
|
|
|
7,551
|
|
On August
9, 2017, Connecting People for Health Co-operative Ltd. (CP4H) was acquired for an undisclosed amount. ZIM recognized its portion
of the proceeds, in the amount $216,901, as a gain on the sale of assets.
On February
9, 2018, ZIM sold 100,000 shares of HostedBizz to HostedBizz, for cancellation, for gross proceeds of $60,000 Canadian dollars
($45,758 United States dollars).
On August
24, 2018, NuvoBio Corporation made an equity investment in Spiderwort Inc. The investment consisted of the purchase of a $10,000
Canadian dollar ($7,725 US dollar) convertible promissory note. The note accrues simple interest of 5% per annum and upon a future
equity financing of Spiderwort Inc. in an amount greater that $3,000,000 Canadian dollars all principal and accrued interest will
convert into the equity securities of the financing at a price per security equal to 80% of the equity financing price per security.
Spiderwort
Inc. is an advanced materials company developing novel, plant derived, biomaterial that will offer new avenues in 3D in vitro
research and in regenerative medicine.
ITEM
2 – QUARTERLY BUSINESS REVIEW
This
Form 6-K contains forward-looking statements regarding our business, financial condition, results of operations, liquidity and
sufficiency of cash reserves, controls and procedures, prospects, revenues expectations, and allocation of resources that are
based on our current expectations, estimates and projections. In addition, other written or oral statements which constitute forward-looking
statements may be made by or on behalf of the registrant. Words such as "expects," "anticipates," "intends,"
"plans," "believes," "seeks," "estimates," or variations of such words and similar expressions
are intended to identify such forward-looking statements. These statements are not guarantees of future performance, and are inherently
subject to risks and uncertainties that are difficult to predict. As a result, actual outcomes and results may differ materially
from the outcomes and results discussed in or anticipated by the forward-looking statements. These risks include, without limitation,
foreign exchange risk, credit risk, fair value risks and key personnel risk and the other risks set forth under “RISK FACTORS”
in our Annual Report on Form 20-F for the fiscal year ended March 31, 2019, and are therefore qualified in their entirety by reference
to the factors specifically addressed in the sections entitled " QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
" in this Form 6-K and “RISK FACTORS” in our Annual Report on Form 20-F for the fiscal year ended March 31, 2019,
as well as those discussed elsewhere in this Form 6-K and our Form 20-F. We operate in a very competitive and rapidly changing
environment. New risks can arise and it is not possible for management to predict all such risks, nor can it assess the impact
of all such risks on our business or the extent to which any factor, or combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place
undue reliance on forward-looking statements as a prediction of actual results. All forward-looking statements contained in this
Form 6-K speak only as of the date of this Form 6-K. We undertake no obligation to revise or update publicly any forward-looking
statements in order to reflect any event or circumstance that may arise after the date of this Form 6-K, other than as required
by law.
The following
discussion includes information from the Selected Financial Data for the three-month and six-month periods ended September 30,
2019 and 2018. These results are not necessarily indicative of results for any future period. You should not rely on
them to predict our future performance.
All financial
information is prepared in accordance with generally accepted accounting principles in the United States ("GAAP") and
is stated in US dollars.
In this
Item 2, references to “we”, “our”, “ZIM, “the Company” and similar terms refer to ZIM.
EXECUTIVE
SUMMARY
Revenue
for the quarter ended September 30, 2018 was $107,680, flat from $107,655 for the same period last year.
Net income
for the quarter was $162,265 as compared to a net loss of $107,952 for the quarter ended September 30, 2018. On a year-to-date
basis net income was $57,317 as compared to a net income of $546,578 for the same period in fiscal 2019. The decrease in net income
is due mainly to the adoption of FASB 2016-01 and the unrealized gain on equity securities of $608,343 that was recognized in
fiscal year 2019.
ZIM had
cash and cash equivalents of $429,202 at September 30, 2019 as compared to cash and cash equivalents of $506,524 at March 31,
2019.
BUSINESS
OVERVIEW
ZIM started
operations as a developer and provider of database software known as ZIM IDE software. ZIM IDE software is used by
companies in the design, development, and management of information databases and mission critical applications. The
Company continues to provide this software and ongoing maintenance services to its client base.
Beginning
in 2002, the Company expanded its business strategy to include opportunities associated with mobile products. Prior
to fiscal 2007, the Company focused on developing products and services for the wireless data network infrastructure known as
“SMS” or “text messaging”. SMS will continue to provide a minimal amount of revenue within
the mobile segment of operations. With the acquisition of Advanced Internet Inc. (AIS) in 2007, the Company also offered mobile
content directly to end users. This service was discontinued March 31, 2013.
In
fiscal 2018, ZIM continued to develop and sell enterprise database software to end users as well as maintain its SMS messaging
product lines. Going forward, management will evaluate opportunities within the enterprise database market as well as the viability
of the SMS product line and make adjustments as may be required.
In 2017,
our wholly-owned subsidiary, NuvoBio signed strategic partnerships and exclusive global licensing agreements with leading drug
research institutes and companies. NuvoBio is currently funding research and development projects in the following areas:
|
·
|
Implementing unique molecular interaction &
analytics using supercomputing technologies to design small peptide drugs that bind to target proteins for cancer therapies;
and
|
|
|
|
|
·
|
The development of bi-specific immunology therapies
for the treatment of kidney cancer.
|
CRITICAL
ACCOUNTING ESTIMATES
We prepare
our condensed consolidated financial statements in accordance with United States GAAP, which requires management to make certain
estimates and apply judgments that affect reported amounts of assets, liabilities, revenues and expenses, and related disclosures
of contingent assets and liabilities. We base our estimates and judgments on historical experience, current trends, and other
factors that management believes to be important at the time the condensed consolidated financial statements are prepared. On
an ongoing basis, management reviews our accounting policies and how they are applied and disclosed in our annual consolidated
financial statements.
There
have been no material changes to our critical accounting estimates from those described in our Form 20-F for the fiscal year ended
March 31, 2019.
RESULTS
OF OPERATIONS FOR THE THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2019 COMPARED TO THE THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2018
The following
discussion includes information derived from the unaudited and not reviewed condensed consolidated statements of operations for
the three and six months ended September 30, 2019 and 2018. The information for the three months and six months ended September
30, 2019, in management's opinion, has been prepared on a basis consistent with the audited consolidated financial statements
for the fiscal year ended March 31, 2019, and includes all adjustments necessary for a fair presentation of the information presented.
These
operating results are not necessarily indicative of results for any future period. You should not rely on them to predict our
future performance.
REVENUES
|
|
Three months ended
September 30, 2019
|
|
As
a %
|
|
Three months ended
September
30, 2018
|
|
As
a %
|
|
|
|
|
|
|
|
|
|
Bulk
SMS
|
|
|
12,227
|
|
|
|
11
|
|
|
|
27,127
|
|
|
|
25
|
|
|
|
|
12,227
|
|
|
|
11
|
|
|
|
27,127
|
|
|
|
25
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Software
|
|
|
17,536
|
|
|
|
17
|
|
|
|
1,828
|
|
|
|
2
|
|
Maintenance
and consulting
|
|
|
77,917
|
|
|
|
72
|
|
|
|
78,700
|
|
|
|
73
|
|
|
|
|
95,453
|
|
|
|
89
|
|
|
|
80,528
|
|
|
|
75
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
Revenues
|
|
|
107,680
|
|
|
|
100
|
|
|
|
107,655
|
|
|
|
100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six
months ended September 30, 2019
|
|
|
|
|
|
|
|
Six
months ended September 30, 2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bulk
SMS
|
|
|
37,104
|
|
|
|
19
|
|
|
|
51,376
|
|
|
|
16
|
|
|
|
|
37,104
|
|
|
|
19
|
|
|
|
51,376
|
|
|
|
16
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Software
|
|
|
20,723
|
|
|
|
11
|
|
|
|
98,963
|
|
|
|
31
|
|
Maintenance
and consulting
|
|
|
138,667
|
|
|
|
70
|
|
|
|
166,825
|
|
|
|
53
|
|
|
|
|
159,930
|
|
|
|
81
|
|
|
|
265,788
|
|
|
|
84
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
Revenues
|
|
|
196,494
|
|
|
|
100
|
|
|
|
317,164
|
|
|
|
100
|
|
Revenue
for the quarter ended September 30, 20198 was $107,680, as compared to $107,655 for the same period last year.
Total
revenues for the six months ended September 30, 2019 were $196,494, a decline from 317,164 for the six months ended September
30, 2018. The decrease in revenue resulted from decreases in all segments of our business.
REVENUES
ANALYSIS BY SERVICE/PRODUCT OFFERING
SOFTWARE,
MAINTENANCE AND CONSULTING
We generate
revenues from the sale of our database product as well as the subsequent maintenance and consulting fees. Total revenues relating
to the ZIM IDE have increased from 1,828 to $17,536 for the quarters ended September 30, 2019 and 2018, respectively. For the
six-month periods ended September 30, 2019 and 2018, revenues decreased from $98,963 to $20,723. Maintenance and consulting revenue
remained flat $78,700 to $77,917 for the quarter and decreased from $166,825 to $138,667 for the six-month period. Declines in
this area are mainly due to the unstable economy in Brazil and subsequent decline in our business activity in Brazil.
We
will continue to allocate resources to the maintenance and development of our database products while we continue to generate
revenues from this product line. Going forward, ZIM will evaluate other opportunities and the viability of the enterprise database
market and make adjustments as may be required.
BULK
SMS
Bulk
SMS messaging gives our customers the ability to send out a single message concurrently to a wide distribution list. Success in
this industry is dependent upon sending large quantities of messages on stable, cost effective telecommunication routes. For the
quarter ended September 30, 2019, we experienced a decrease in revenues from $27,127, for the period ended September 30, 2018,
to $12,227. We experienced a year-to-date revenue decrease from $51,376 for the six months ended September 30, 2018, to $37,104
for the six months ended September 30, 2019. In general, bulk-messaging customers choose the service provider that is offering
the lowest cost route. Different aggregators are able to negotiate different price points based on the traffic they are able to
guarantee to the mobile operators. Due to the size of our competitors, and our competitors’ ability to negotiate better
terms, there can be no guarantee that we will have routes that are the most cost effective in the future. We are not focusing
on expanding this area of the business. As a result, we do not expect to see any further growth in our bulk messaging revenue
during the remainder of fiscal 2020.
OPERATING
EXPENSES
|
|
Three
months
ended September
30, 2019
|
|
Three
months ended September
30, 2018
|
|
Period
to period change
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenues
|
|
|
5,867
|
|
|
|
4,789
|
|
|
|
1,078
|
|
Selling, general
and administrative
|
|
|
137,661
|
|
|
|
176,458
|
|
|
|
(38,797
|
)
|
Research
and development
|
|
|
47,323
|
|
|
|
67,063
|
|
|
|
(19,740
|
)
|
|
|
|
190,851
|
|
|
|
248,310
|
|
|
|
(57,459
|
)
|
|
|
Six months ended
September 30, 2019
|
|
Six months ended
September 30, 2018
|
|
Period
to period change
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenues
|
|
|
10,679
|
|
|
|
8,139
|
|
|
|
2,540
|
|
Selling, general
and administrative
|
|
|
296,765
|
|
|
|
295,996
|
|
|
|
769
|
|
Research
and development
|
|
|
99,742
|
|
|
|
119,525
|
|
|
|
(19,783
|
)
|
|
|
|
407,186
|
|
|
|
423,660
|
|
|
|
(16,474
|
)
|
COST
OF REVENUE
|
|
Three
months ended
September 30, 2019
|
|
Three months ended
September 30, 2018
|
|
|
|
$
|
|
|
|
$
|
|
Mobile
|
|
|
|
|
|
|
|
|
Revenues
|
|
|
12,227
|
|
|
|
27,127
|
|
Cost of revenues
|
|
|
(355
|
)
|
|
|
(665
|
)
|
Gross
margin
|
|
|
11,872
|
|
|
|
26,462
|
|
|
|
|
|
|
|
|
|
|
Gross margin percentage
|
|
|
97
|
%
|
|
|
98
|
%
|
|
|
|
|
|
|
|
|
|
Software
|
|
|
|
|
|
|
|
|
Revenues
|
|
|
95,453
|
|
|
|
80,528
|
|
Cost of revenues
|
|
|
(5,512
|
)
|
|
|
(4,124
|
)
|
Gross
margin
|
|
|
89,941
|
|
|
|
76,404
|
|
|
|
|
|
|
|
|
|
|
Gross margin percentage
|
|
|
94
|
%
|
|
|
95
|
%
|
|
|
Six
months ended September 30, 2019
|
|
Six
months ended September 30, 2018
|
|
|
|
$
|
|
|
|
$
|
|
Mobile
|
|
|
|
|
|
|
|
|
Revenues
|
|
|
37,104
|
|
|
|
51,376
|
|
Cost of revenues
|
|
|
(685
|
)
|
|
|
(1,308
|
)
|
Gross
margin
|
|
|
36,419
|
|
|
|
50,068
|
|
|
|
|
|
|
|
|
|
|
Gross margin percentage
|
|
|
98
|
%
|
|
|
97
|
%
|
|
|
|
|
|
|
|
|
|
Software
|
|
|
|
|
|
|
|
|
Revenues
|
|
|
159,390
|
|
|
|
265,788
|
|
Cost of revenues
|
|
|
(9,994
|
)
|
|
|
(6,831
|
)
|
Gross
margin
|
|
|
149,396
|
|
|
|
258,957
|
|
|
|
|
|
|
|
|
|
|
Gross margin percentage
|
|
|
94
|
%
|
|
|
97
|
%
|
SELLING,
GENERAL AND ADMINISTRATIVE
Selling,
general and administrative expenses for the quarters ended September 30, 2019 and September 30, 2018 were $137,661 and $176,458,
respectively. On a year-to-date basis expenses increased slightly by $769 from $295,996 for the first half of fiscal 2018 to $296,765
for the first half of fiscal 2019.
STOCK-BASED
COMPENSATION
For the
three months ended September 30, 2019 and September 30, 2018, the Company recognized compensation expense for employees and consultants
of $806 and $335, respectively. On a year-to-date basis, stock-based compensation increased from $335 for the first half of fiscal
2019 to $806 for the first half of fiscal 2020. The Company does not have any non-vested awards.
RESEARCH
AND DEVELOPMENT
Research
and development expenses for the quarters ended September 30, 2019 and 2018 were $47,323 and $67,063, respectively. On a year-to-
date basis, research and development expenses decreased from $119,525 for the first half of fiscal 2019 to $99,742 for the first
half of fiscal 2020 and are reflective of decreased investment in research and development labour.
NET
INCOME
Net income
for the quarter was $162,265 as compared to a net loss of $107,952 for the quarter ended September 30, 2018. On a year-to-date
basis net income was $57,317 as compared to a net income of $546,578 for the same period in fiscal 2019. The decrease in net income
is due mainly to the adoption of FASB 2016-01 and the unrealized gain on equity securities of $608,343 that was recognized in
fiscal year 2019.
LIQUIDITY
AND CAPITAL RESOURCES
At September
30, 2019, ZIM had cash and cash equivalents of $429,202 and working capital of $679,320, as compared to cash and cash equivalents
of $506,524 and working capital of $652,488 at March 31, 2019.
Cash
flows for the fiscal periods were as follows:
|
|
Six months ended
September 30, 2019
|
|
Six months ended
September 30, 2018
|
|
|
|
$
|
|
|
|
$
|
|
Cash
flows generated by (used in) operating activities
|
|
|
(47,978
|
)
|
|
|
117,950
|
|
Cash flows used
in investing activities
|
|
|
(6,576
|
)
|
|
|
(6,054
|
)
|
Cash flows provided
by financing activities
|
|
|
—
|
|
|
|
—
|
|
At September
30, 2019, the Company had a working capital line from its principal banker for approximately $37,756 in addition to a cash and
cash equivalent balance of $429,202. Management believes that these funds, together with cash from on-going operations, may not
be sufficient to fund existing operations for the next 12 months. Management is currently investigating and evaluating options
that may include recapitalization of the Company and pursuing other ventures of a different nature.
Future
liquidity and cash requirements will depend on a wide range of factors, including the level of success the Company has in executing
its strategic plan as well as its ability to maintain business in existing operations and its ability to raise additional financing.
If ZIM’s expenses surpass the funds available or if ZIM requires additional expenditures to grow the business, the Company
may be unable to obtain the necessary funds and ZIM may have to curtail or suspend some or all of its business operations, which
would likely have a material adverse effect on its business relationships, financial results, financial condition and prospects,
as well as on the ability of shareholders to recover their investment.
OFF-BALANCE
SHEET ARRANGEMENTS
The Company
does not have any off-balance sheet arrangements.
SUBSEQUENT
EVENTS
On October
15, 2019, Spiderwort Inc. completed a qualifying equity financing in an amount greater that $3,000,000 Canadian dollars. NuvoBio
automatically converted securities in Spiderwort to Class B voting common shares at a price of 80% of the financing price. This
represents an unrealized gain of 25% or $2,500 Canadian dollars ($1,888 United States dollars).
ITEM
3 – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS
FOREIGN
EXCHANGE RISK
The Company
operates internationally, giving rise to significant exposure to market risks from fluctuations and the degree of volatility of
foreign exchange rates. The Company is exposed to exchange risk due to the following financial instruments denominated in foreign
currencies.
Cash
and cash equivalents includes the following amounts in their source currency:
|
|
September 30, 2019
|
|
March
31, 2019
|
|
|
|
|
|
Canadian
dollars
|
|
|
237,378
|
|
|
|
131,463
|
|
US
dollars
|
|
|
—
|
|
|
|
153,406
|
|
Brazilian
reals
|
|
|
1,039,742
|
|
|
|
1,013,757
|
|
Accounts
receivable include the following amounts receivable in their source currency:
|
|
September 30, 2019
|
|
March
31, 2019
|
|
|
|
|
|
Canadian
dollars
|
|
|
297,115
|
|
|
|
44,287
|
|
US
dollars
|
|
|
17,452
|
|
|
|
4,548
|
|
Brazilian
reals
|
|
|
164,698
|
|
|
|
85,476
|
|
Accounts
payable include the following amounts payable in their source currency:
|
|
September 30, 2019
|
|
March
31, 2019
|
|
|
|
|
|
Canadian
dollars
|
|
|
11,221
|
|
|
|
44.537
|
|
US
dollars
|
|
|
11,303
|
|
|
|
3.275
|
|
Brazilian
reals
|
|
|
772
|
|
|
|
772
|
|
Accrued
liabilities include the following accruals in their source currency:
|
|
September 30, 2019
|
|
March
31, 2019
|
|
|
|
|
|
Canadian
dollars
|
|
|
16,445
|
|
|
|
22,397
|
|
Brazilian reals
|
|
|
36,483
|
|
|
|
18,412
|
|
The Company
does not use derivative financial instruments to reduce its foreign exchange risk exposure.
CREDIT
RISK
The Company
is exposed to credit-related losses in the event of non-performance by counterparties to financial instruments. Credit exposure
is minimized by dealing with only creditworthy counterparties in accordance with established credit approval policies.
Concentration
of credit risk in accounts receivable is indicated below by the percentage of the total balance receivable from customers in the
specified geographic area:
|
|
September 30, 2019
|
|
|
|
March 31, 2019
|
Canada
|
|
|
80
|
%
|
|
|
|
55
|
%
|
North America, excluding Canada
|
|
|
6
|
%
|
|
|
|
8
|
%
|
South America
|
|
|
14
|
%
|
|
|
|
37
|
%
|
|
|
|
100
|
%
|
|
|
|
100
|
%
|
FAIR
VALUE
The carrying
values of cash and cash equivalents, accounts receivable, investment tax credits receivable, lines of credit, accounts payable
and accrued liabilities approximate their fair value due to the relatively short periods to maturity of the instruments.
KEY
PERSONNEL RISK
We currently
depend heavily on the services of Dr. Michael Cowpland and Mr. James Stechyson. The loss of the services of Dr. Cowpland and Mr.
Stechyson and other key personnel could affect our performance in a material and adverse way.
ITEM
3 – 2019 ANNUAL GENERAL MEETING
The Annual
Meeting of Shareholders of ZIM Corporation (ZIM or the Company) was held at the offices of ZIM at 150 Isabella Street, Suite 150,
Ottawa, Ontario, Canada K1S 1V7, on Thursday, September 23, 2019, beginning at 11:00 a.m. At the meeting votes were taken with
regard to the following proposals:
|
1.
|
To
re-elect four directors to the Board of Directors for a three-year period;
|
|
|
|
|
2.
|
To
ratify the appointment of MNP LLP as the Company’s registered public accounting
firm; and
|
|
|
|
|
3.
|
To
transact such other business as may properly come before the meeting or any adjournment
thereof.
|
Shareholders
of record at the close of business on August 19, 2019, were entitled to vote at the meeting. The notice of the meeting and the
accompanying management proxy circular were mailed to shareholders on or about August 26, 2019.
The duly
appointed Inspectors of Election reported and certified the results of ballots cast as:
PROPOSAL
1: Election of the following director nominees to serve for the following three years and until their successors are elected:
|
|
FOR
|
|
|
AGAINST
|
Michael Cowpland:
|
|
|
6,272,598
|
|
|
|
3,715
|
|
James Stechyson:
|
|
|
6,272,598
|
|
|
|
3,715
|
|
Steven Houck:
|
|
|
6,272,598
|
|
|
|
3,715
|
|
Donald Gibbs:
|
|
|
6,272,598
|
|
|
|
3,715
|
|
PROPOSAL
2: Ratification of the appointment of MNP LLP as the Company’s registered public accounting firm for the fiscal year
ending March 31, 2020.
FOR
|
|
AGAINST
|
|
ABSTAIN
|
|
6,275,093
|
|
|
|
1,210
|
|
|
|
10
|
|
No other
business was proposed or conducted at the meeting.
SIGNATURES
In accordance
with the requirements of the Exchange Act, the registrant has caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
ZIM Corporation
Registrant
DATE
|
SIGNATURE
|
November
4, 2018
|
/s/
Dr. Michael Cowpland
Dr.
Michael Cowpland, President and Chief Executive Officer
|
DATE
|
SIGNATURE
|
November
4, 2018
|
/s/
John Chapman
John
Chapman, Chief Financial Officer
|
17
Zim (CE) (USOTC:ZIMCF)
Historical Stock Chart
From Jan 2025 to Feb 2025
Zim (CE) (USOTC:ZIMCF)
Historical Stock Chart
From Feb 2024 to Feb 2025